BCR-ABL1 kinase domain mutation analysis by next generation sequencing detected additional mutations in chronic myeloid leukemia patients with suboptimal response to imatinib

Click to increase image sizeClick to decrease image size

Disclosure statement

No potential conflict of interest was reported by the author(s).

Acknowledgements

RVS, VM and PB are supported by Wellcome DBT India Alliance (IA/S/17/1/503118, IA/CPHS/18/1/503930 and IA/S/15/1/501842) respectively.

ESB is supported by DST Inspire fellowship, Government of India.

The help provided by Dr. Eunice S. Edison in managing the DNA sequencing core facility is gratefully acknowledged.

PB-Poonkuzhali Balasubramanian.

RVS- Shaji Ramachandran Velayudhan.

VM-Vikram Mathews.

ESB-Esther Sathya Bama Benjamin R.

Correction Statement

This article has been corrected with minor changes. These changes do not impact the academic content of the article.

Additional information

Funding

This study is supported by a Centre of Excellence grant from Department of Biotechnology India: BT/COE/34/SP13432/2015 and Indian Council of Medical Research Centre for Advanced Research grant 70/14/14-CAR to Dr. Poonkuzhali Balasubramanian.